Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Polycythemia vera remains a chronic condition with no definitive cure, but its management landscape is steadily evolving

  60% confidence

• The polycythemia vera market is set for expansion by 2036, with nine companies expected to enter the market with new therapies

  60% confidence

• The polycythemia vera market is poised for significant expansion at 8.9% CAGR through 2036, fueled by increasing prevalence, unmet clinical needs, and upcoming therapeutic innovations

  60% confidence

• JAKAFI continues to demonstrate strong commercial momentum, driven by robust demand in polycythemia vera and graft-versus-host disease, despite approaching patent expiry in 2028

  60% confidence

Cited in these Via News reports

• Gilead Buys Ouro Medicines, Gives Spin-Off $500M to Build Global Inflammation Pipeline →
• Gilead and Europe's Lakefront Close $500M Ouro Deal in Cross-Atlantic Biotech Push →